ZENBEXUS Trademark

Trademark Overview


On Friday, October 17, 2025, a trademark application was filed for ZENBEXUS with the United States Patent and Trademark Office. The USPTO has given the ZENBEXUS trademark a serial number of 99448542. The federal status of this trademark filing is NON-FINAL ACTION - MAILED as of Monday, March 16, 2026. This trademark is owned by Celgene Corporation. The ZENBEXUS trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment and prevention of obesity, cardiovascular diseases, central nervous system diseases, metabolic disorders, stroke, cancer, inflammatory diseases, respiratory diseases, infectious diseases, auto-immune diseases, solid organ transplant rejection, autoinflammatory disease, blood disease, multiple sclerosis, ulcerative colitis, cystic fibrosis, arthritis, and musculoskeletal and skin disease; Antivirals; Antibodies for medical purposes; Biological preparations for the treatment of cancer; Anticoagulants; Stem cells for medical purposes; Radiopharmaceutical preparations for the treatment of cancer and solid tumors; Diagnostic radiopharmaceutical preparations; Diagnostic preparations for medical purposes
zenbexus

General Information


Serial Number99448542
Word MarkZENBEXUS
Filing DateFriday, October 17, 2025
Status641 - NON-FINAL ACTION - MAILED
Status DateMonday, March 16, 2026
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing3 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s)
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Indication of Colors claimedColor is not claimed as a feature of the mark.
Description of MarkThe mark consists of the word "ZENBEXUS" in stylized font positioned under a design of a stylized fin.
Goods and ServicesPharmaceutical preparations for the treatment and prevention of obesity, cardiovascular diseases, central nervous system diseases, metabolic disorders, stroke, cancer, inflammatory diseases, respiratory diseases, infectious diseases, auto-immune diseases, solid organ transplant rejection, autoinflammatory disease, blood disease, multiple sclerosis, ulcerative colitis, cystic fibrosis, arthritis, and musculoskeletal and skin disease; Antivirals; Antibodies for medical purposes; Biological preparations for the treatment of cancer; Anticoagulants; Stem cells for medical purposes; Radiopharmaceutical preparations for the treatment of cancer and solid tumors; Diagnostic radiopharmaceutical preparations; Diagnostic preparations for medical purposes

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, October 17, 2025
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameCelgene Corporation
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressPrinceton, NJ 08543
US

Trademark Events


Event DateEvent Description
Friday, October 17, 2025NEW APPLICATION ENTERED
Friday, October 17, 2025APPLICATION FILING RECEIPT MAILED
Wednesday, March 4, 2026NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, March 4, 2026NOTICE OF DESIGN SEARCH CODE E-MAILED
Thursday, March 5, 2026ASSIGNED TO EXAMINER
Monday, March 16, 2026NON-FINAL ACTION WRITTEN
Monday, March 16, 2026NON-FINAL ACTION E-MAILED
Monday, March 16, 2026NOTIFICATION OF NON-FINAL ACTION E-MAILED